Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults

PHASE3RecruitingINTERVENTIONAL
Enrollment

846

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

January 31, 2030

Conditions
Non-Invasive Ventilation
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation (IMV) that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium

OTHER

Placebo Control

Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans

Trial Locations (6)

V3T 0H1

NOT_YET_RECRUITING

Fraser Health Authority, Surrey

K6V 1S8

NOT_YET_RECRUITING

Brockville General Hospital, Brockville

L8N 4A6

RECRUITING

St. Joseph's Healthcare Hamilton, Hamilton

L8V 1C3

NOT_YET_RECRUITING

Juravinski Hospital and Cancer Centre, Hamilton

M2K 1E1

NOT_YET_RECRUITING

North York General Hospital, Toronto

M5G 1X5

NOT_YET_RECRUITING

Sinai Health System, Toronto

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

lead

St. Joseph's Healthcare Hamilton

OTHER

NCT06259565 - Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults | Biotech Hunter | Biotech Hunter